​​​Aduhelm™​​​ for treatment of Alzheimer’s disease considered experimental/investigational

July 8, 2021

​Aduhelm (aducanumab-avwa) injection is considered experimental/investigational for Independence commercial members and is not covered for treatment of Alzheimer's disease. 

We continue to monitor for the Centers for Medicare & Medicaid Services coverage position so that we can be sure our coverage policies for Medicare Advantage members align with their decisions.

We have evaluated the published peer-reviewed literature on the evidence of Aduhelm's safety and effectiveness in treating Alzheimer's disease. We have concluded that it does not sufficiently show that the drug's clinical benefits outweigh its harms or that it reduces progression of the disease.

Other uses for Aduhelm and services associated with Aduhelm, including but not limited to radiological examinations, are not covered. 

For more information about the coverage of Aduhelm, including background and coding, please read our News Articles on the Commercial and Medicare Advantage Medical and Claim Payment Policy Portals.​